Bio-Rad Laboratories Financial Statements (BIO)
|
|
|
|
Report date
|
|
|
28.10.2021 |
11.02.2022 |
31.12.2022 |
17.02.2023 |
16.02.2024 |
|
31.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
|
2 923 |
2 802 |
2 802 |
2 671 |
|
2 549 |
|
Operating Income, bln rub |
|
|
|
489.4 |
482.6 |
482.6 |
383.8 |
|
275.1 |
|
EBITDA, bln rub |
? |
|
|
5 628 |
-2 375 |
-4 489 |
-608.3 |
|
136.4 |
|
Net profit, bln rub |
? |
|
|
4 254 |
-3 628 |
-3 628 |
-637.3 |
|
-475.2 |
|
|
OCF, bln rub |
? |
|
|
656.5 |
194.4 |
194.4 |
374.9 |
|
495.3 |
|
CAPEX, bln rub |
? |
|
|
120.8 |
112 782 |
114.2 |
156.7 |
|
247.4 |
|
FCF, bln rub |
? |
|
|
535.7 |
194.4 |
80.3 |
218.3 |
|
577.7 |
|
Dividend payout, bln rub
|
|
|
|
0.000 |
68 184 |
0.000 |
0.000 |
|
47.5 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
-10.00% |
|
|
OPEX, bln rub |
|
|
|
1 151 |
1 085 |
1 085 |
1 048 |
|
1 118 |
|
Cost of production, bln rub |
|
|
|
1 282 |
1 235 |
1 235 |
1 240 |
|
1 156 |
|
R&D, bln rub |
|
|
|
271.7 |
256.9 |
256.9 |
226.9 |
|
307.3 |
|
Interest expenses, bln rub |
|
|
|
1.55 |
38.1 |
38.1 |
49.4 |
|
48.9 |
|
|
Assets, bln rub |
|
|
19 953 |
17 776 |
13 502 |
13 502 |
12 299 |
|
10 603 |
|
Net Assets, bln rub |
? |
|
15 332 |
13 667 |
9 615 |
9 615 |
8 741 |
|
7 488 |
|
Debt, bln rub |
|
|
12.4 |
11.0 |
1 198 |
1 198 |
1 405 |
|
1 388 |
|
Cash, bln rub |
|
|
1 343 |
875.5 |
434.2 |
1 796 |
1 613 |
|
1 629 |
|
Net debt, bln rub |
|
|
-1 330 |
-864.5 |
764.0 |
-598.1 |
-207.4 |
|
-241.3 |
|
|
Ordinary share price, rub |
|
|
746.0 |
755.6 |
420.5 |
420.5 |
322.9 |
|
281.3 |
|
Number of ordinary shares, mln |
|
|
|
29.8 |
29.8 |
29.8 |
29.2 |
|
27.9 |
|
|
Market cap, bln rub |
|
|
0 |
22 539 |
12 524 |
12 524 |
9 431 |
|
7 862 |
|
EV, bln rub |
? |
|
-1 330 |
21 675 |
13 288 |
11 926 |
9 224 |
|
7 621 |
|
Book value, bln rub |
|
|
14 863 |
13 066 |
8 877 |
8 877 |
8 007 |
|
6 765 |
|
|
EPS, rub |
? |
|
|
142.6 |
-121.8 |
-121.8 |
-21.8 |
|
-17.0 |
|
FCF/share, rub |
|
|
|
18.0 |
6.53 |
2.70 |
7.47 |
|
20.7 |
|
BV/share, rub |
|
|
|
438.0 |
298.0 |
298.0 |
274.1 |
|
242.1 |
|
|
EBITDA margin, % |
? |
|
|
192.6% |
-84.8% |
-160.2% |
-22.8% |
|
5.35% |
|
Net margin, % |
? |
|
|
145.6% |
-129.5% |
-129.5% |
-23.9% |
|
-18.6% |
|
FCF yield, % |
? |
|
0.00% |
2.38% |
1.55% |
0.64% |
2.31% |
|
7.35% |
|
ROE, % |
? |
|
0.00% |
31.1% |
-37.7% |
-37.7% |
-7.29% |
|
-6.35% |
|
ROA, % |
? |
|
0.00% |
23.9% |
-26.9% |
-26.9% |
-5.18% |
|
-4.48% |
|
|
P/E |
? |
|
|
5.30 |
-3.45 |
-3.45 |
-14.8 |
|
-16.5 |
|
P/FCF |
|
|
|
42.1 |
64.4 |
156.0 |
43.2 |
|
13.6 |
|
P/S |
? |
|
|
7.71 |
4.47 |
4.47 |
3.53 |
|
3.08 |
|
P/BV |
? |
|
0.00 |
1.73 |
1.41 |
1.41 |
1.18 |
|
1.16 |
|
EV/EBITDA |
? |
|
|
3.85 |
-5.59 |
-2.66 |
-15.2 |
|
55.9 |
|
Debt/EBITDA |
|
|
|
-0.15 |
-0.32 |
0.13 |
0.34 |
|
-1.77 |
|
|
R&D/CAPEX, % |
|
|
|
224.9% |
0.23% |
225.0% |
144.8% |
|
124.2% |
|
|
CAPEX/Revenue, % |
|
|
|
4.13% |
4 025% |
4.07% |
5.87% |
|
9.71% |
|
| Bio-Rad Laboratories shareholders |
